March 26, 2025 at 2PM EST

Preparing to launch an HCP-administered treatment can be one of the most challenging opportunities for manufacturer commercial teams in their careers. HCP-administered products require use of a completely different “playbook” and “commercialization rules” (compared to self-administered treatments) given the dynamics of buy and bill among sites of administration and ASP-based reimbursement. The playbook and rules have far-reaching implications for how a manufacturer should develop its pre-commercialization strategy, encompassing almost all areas of market access. In this webinar we provide an overview of the HCP-administered playbook and essential considerations for manufacturers who are preparing to launch an HCP-administered specialty or orphan / rare product. Specific topics covered will be: 

• Importance of ASP-Stewardship and Site of Administration Net Cost Recovery  
• Essential Considerations for Design of a Product’s Pricing Strategy, Payer Strategy, Channel Strategy, Patient Services Strategy, and Discounting / Rebating Strategy  
• Gross-to-Net and Government Pricing Considerations 
• Scenarios and Conditions for When the Playbook and Rules May Not Apply 

Please join us for this informative webinar as we discuss the multitude of challenges that manufacturers must navigate when preparing to commercialize an HCP-administered treatment.

Joey Miller
Senior Principal

Brett Casper
Senior Principal